Skip to content
menu-icon-lq
close-icon-lq

Aarno Dietz

Professor (Clinical Research)
Kuopio University Hospital & University of Eastern Finland
Finland

Professor Aarno Dietz is an ENT specialist and otologist with over 25 years of experience in clinical audiology, otologic surgery, and lateral skull base surgery. He holds the title of Professor for Clinical Research and is the Chair of the Center of Excellence for Sense Organ Diseases at Kuopio University Hospital. He leads the Kuopio Cochlear Implant Research Group, the "Towards Better Hearing" project, the Research to Business project TrueHear, and the EU co-funded Hearing Valley project at the University of Eastern Finland, driving advancements in hearing healthcare innovation and research. A recognized expert in the field, Professor Dietz is part of the European Medical Agency (EMA) Expert Panel on medical devices and in vitro diagnostics, serving as Chair of the Subpanel for Hearing. Through his clinical expertise, pioneering research, and leadership in transformative projects, he continues to set benchmarks in audiology and otology, significantly improving patient outcomes, establishing best practices and advancing medical and surgical solutions for hearing loss.

Aiheet

Clinicians perspective on the optimal use of laboratory results in diagnosis and monitoring of diabetes type 2

Quality in Laboratory Medicine
Laboratory Results Fit for Purpose
7.2.2025 12:45 - 13:15 | Hall 209 - Aurevia

From a clinician's perspective, the optimal use of laboratory results is crucial in the diagnosis and monitoring of Type 2 diabetes. Laboratory tests provide objective data that help in confirming a diagnosis, assessing the severity of the disease, and monitoring the effectiveness of treatment plans. Diagnosis: The primary laboratory tests used for diagnosing Type 2 diabetes include fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c). The HbA1c test is particularly valuable as it reflects average blood glucose levels over the past six to eight weeks, providing a comprehensive view of a patient's glucose control. Clinicians rely on these tests to make an accurate diagnosis and to differentiate between Type 1 and Type 2 diabetes. Monitoring: Once diagnosed, regular monitoring of blood glucose levels is essential. HbA1c remains a cornerstone in this process, typically measured every six months. It helps clinicians evaluate long-term glucose control and adjust treatment plans accordingly. Additionally, periodic testing of fasting glucose and postprandial glucose levels can provide insights into daily glucose fluctuations and the effectiveness of dietary and pharmacological interventions. Other Laboratory Tests: Clinicians also use other laboratory tests to monitor complications associated with diabetes. These include lipid profiles to assess cardiovascular risk, kidney function tests (e.g., serum creatinine and urine albumin) to detect early signs of nephropathy, and liver function tests to monitor for non-alcoholic fatty liver disease, which is common in diabetic patients. In summary, the optimal use of laboratory results enables clinicians to diagnose Type 2 diabetes accurately, tailor treatment plans, and monitor for complications, ultimately improving patient outcomes.